A first in-human, multicenter, open-label, dosefinding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2020
This article has no abstract
Epistemonikos ID: 11af8cb7f659f550ca9b6e8fbf775897b3be8db8
First added on: Feb 12, 2025